Screener
Zevra Therapeutics, Inc. ZVRA Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Total other (expense) income | (3,983) | 147,945 | (11,324) | 151,390 |
| Income before income taxes | 12,794 | 76,906 | 57,599 | 74,989 |
| Income tax expense | (4,042) | (2,199) | (10,957) | (3,381) |
| Net income | $8,752 | $74,707 | $46,642 | $71,608 |
| Net income per share of common stock: | ||||
| Basic | $0.14 | $1.24 | $0.76 | $1.20 |
| Diluted | $0.14 | $1.21 | $0.74 | $1.16 |
| Weighted-average shares of common stock outstanding: |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s net income?
- Zevra Therapeutics, Inc. (ZVRA) reported net income of $8.75M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s net income changed year-over-year?
- Zevra Therapeutics, Inc.'s net income decreased by 88.3% year-over-year, from $74.71M to $8.75M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s net income has grown at a 113.5% compound annual growth rate (CAGR), from -$8.56M to $83.23M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Zevra Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude